CL2019002367A1 - Composiciones y métodos para la transducción de tumores. - Google Patents
Composiciones y métodos para la transducción de tumores.Info
- Publication number
- CL2019002367A1 CL2019002367A1 CL2019002367A CL2019002367A CL2019002367A1 CL 2019002367 A1 CL2019002367 A1 CL 2019002367A1 CL 2019002367 A CL2019002367 A CL 2019002367A CL 2019002367 A CL2019002367 A CL 2019002367A CL 2019002367 A1 CL2019002367 A1 CL 2019002367A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- methods
- cells
- tumor transduction
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000026683 transduction Effects 0.000 title 1
- 238000010361 transduction Methods 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
LA INVENCIÓN SE REFIERE A PRODUCTOS TERAPÉUTICOS CONTRA EL CÁNCER, EN PARTICULAR, EL SISTEMA PARA HACER QUE LAS CÉLULAS CANCEROSAS SEAN MÁS SUSCEPTIBLES A CÉLULAS EFECTORAS MEDIANTE LA INTRODUCCIÓN DE DIANAS DE TERAPIA CELULAR EN CÉLULAS CANCEROSAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762462108P | 2017-02-22 | 2017-02-22 | |
US201762541409P | 2017-08-04 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002367A1 true CL2019002367A1 (es) | 2020-04-13 |
Family
ID=63254118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002367A CL2019002367A1 (es) | 2017-02-22 | 2019-08-22 | Composiciones y métodos para la transducción de tumores. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200306375A1 (es) |
EP (1) | EP3585426A4 (es) |
JP (1) | JP2020508662A (es) |
KR (1) | KR20190141655A (es) |
CN (1) | CN110691610A (es) |
AU (1) | AU2018225153A1 (es) |
BR (1) | BR112019017401A2 (es) |
CA (1) | CA3054302A1 (es) |
CL (1) | CL2019002367A1 (es) |
IL (1) | IL268815A (es) |
MA (1) | MA47611A (es) |
MX (1) | MX2019010039A (es) |
WO (1) | WO2018156791A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2020246563A1 (es) * | 2019-06-05 | 2020-12-10 | ||
EP4076522A4 (en) * | 2019-12-16 | 2024-04-10 | 2Seventy Bio Inc | ANTI-BCMA-CAR ANTIBODIES, CONJUGATES AND METHODS OF USE |
CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
EP4211164A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Single domain antibodies against cd33 |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
US20230210953A1 (en) * | 2021-12-16 | 2023-07-06 | Deka Biosciences, Inc. | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer |
WO2023178073A2 (en) * | 2022-03-15 | 2023-09-21 | Celledit Llc | Use of antigen presenting cells to enhance car-t cell therapy |
WO2023201238A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
WO2024022602A1 (en) | 2022-07-28 | 2024-02-01 | Akamis Bio Ltd | Virus encoding transgenes to complement cellular therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
EP1871417B1 (en) * | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
JP5479087B2 (ja) * | 2006-04-07 | 2014-04-23 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | アデノ随伴ウイルスファージ粒子に関する方法および組成物 |
AT504160A1 (de) * | 2006-09-11 | 2008-03-15 | Ralf Dr Kircheis | Verwendung einer mehrkomponenten-tumorvakzine |
US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
EP2861622A4 (en) * | 2012-06-15 | 2016-06-01 | Sinomab Bioscience Ltd | Anti-idiotypic anti-CD22 antibodies and uses thereof |
GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
US9701758B2 (en) * | 2013-05-24 | 2017-07-11 | Board Of Regents, The University Of Texas System | Anti-CD19 scFv (FMC63) polypeptide |
CA2937711C (en) * | 2014-02-14 | 2020-10-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
BR112018070676A2 (pt) * | 2016-04-15 | 2019-02-05 | Zymeworks Inc | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos |
-
2018
- 2018-02-22 US US16/487,752 patent/US20200306375A1/en not_active Abandoned
- 2018-02-22 KR KR1020197027552A patent/KR20190141655A/ko not_active Application Discontinuation
- 2018-02-22 AU AU2018225153A patent/AU2018225153A1/en not_active Abandoned
- 2018-02-22 CN CN201880025773.1A patent/CN110691610A/zh active Pending
- 2018-02-22 BR BR112019017401A patent/BR112019017401A2/pt not_active IP Right Cessation
- 2018-02-22 MX MX2019010039A patent/MX2019010039A/es unknown
- 2018-02-22 WO PCT/US2018/019266 patent/WO2018156791A1/en unknown
- 2018-02-22 EP EP18757760.6A patent/EP3585426A4/en not_active Withdrawn
- 2018-02-22 CA CA3054302A patent/CA3054302A1/en not_active Abandoned
- 2018-02-22 JP JP2019545730A patent/JP2020508662A/ja active Pending
- 2018-02-22 MA MA047611A patent/MA47611A/fr unknown
-
2019
- 2019-08-21 IL IL26881519A patent/IL268815A/en unknown
- 2019-08-22 CL CL2019002367A patent/CL2019002367A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018156791A1 (en) | 2018-08-30 |
BR112019017401A2 (pt) | 2020-04-14 |
MA47611A (fr) | 2020-01-01 |
JP2020508662A (ja) | 2020-03-26 |
EP3585426A1 (en) | 2020-01-01 |
EP3585426A4 (en) | 2020-11-25 |
KR20190141655A (ko) | 2019-12-24 |
CN110691610A (zh) | 2020-01-14 |
AU2018225153A1 (en) | 2019-09-19 |
CA3054302A1 (en) | 2018-08-30 |
MX2019010039A (es) | 2020-01-13 |
IL268815A (en) | 2019-10-31 |
US20200306375A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002367A1 (es) | Composiciones y métodos para la transducción de tumores. | |
CL2018001108A1 (es) | Composiciones y métodos para transducción de tumores | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
CL2015003731A1 (es) | Inhibidores de bromodominios | |
NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
AU2016249002B2 (en) | Compositions for modulating C90RF72 expression | |
NZ746680A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
UY36075A (es) | Derivados de tubulisina | |
BR112017010761A2 (pt) | tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia | |
NZ739133A (en) | Cellular targeted active ingredient delivery system | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
BR112019025388A2 (pt) | Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal | |
PH12019500135A1 (en) | Methods of treating prostate cancer | |
BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
BR112017004444A2 (pt) | novos anticorpos anti-mfi2 e métodos de uso | |
WO2016164743A3 (en) | Cd38 ligand-drug conjugates for targeted cancer therapy | |
PH12017501790A1 (en) | Pyrrolidine carboxamido derivatives and methods for preparing and using the same |